Aotecarbio (688606.SH): Completion of the fundraising project and use of the remaining funds to permanently supplement the company's working capital.
On July 19th, Gelunhui announced that Otaibio (688606.SH) held its 3rd Board of Directors and 3rd Supervisory Board 5th meeting on July 19th, 2024. The Proposal on "Partially closing the raised investment projects and using the remaining funds to supplement the permanent working capital" was deliberated and approved. The company agreed to invest the raised funds in the projects "New industrialized technology upgrade project for the annual production of 0.265 billion people's diagnostic reagents" and "IVD R&D Center Construction Project" (referred to as the "raised investment projects") and use the remaining raised funds to supplement the company's permanent working capital.
Aotec Biology (688606.SH) will distribute a dividend of 1.5 yuan per share for the year 2023, with a registration date of June 19th.
Otaibiology (688606.SH) announced that the company will implement annual equity distribution in 2023, distributing per share...
Lacklustre Performance Is Driving Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) 25% Price Drop
Aotai Biotech (688606.SH): Proposed 1.3 Million Restricted Stock Incentive Plan
Gelonghui, May 14 | Aotai Biotech (688606.SH) announced the 2024 restricted stock incentive plan. The company plans to grant 1.3 million restricted shares to incentive recipients, accounting for about 1.64% of the company's total share capital of 79.280855 million shares when the draft incentive plan was announced. Among them, 1.19 million shares were granted for the first time, accounting for about 1.50% of the company's total share capital at the time the draft incentive plan was announced, accounting for about 91.54% of the total equity granted; 110 million shares were reserved, accounting for about 0.14% of the company's total share capital when the draft incentive plan was announced, accounting for about 0.14% of the company's total share capital at the time the draft incentive plan was announced, accounting for about
Some Investors May Be Worried About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital
Aotai Biotech (688606.SH)'s net profit of 44.79 million yuan in the first quarter increased 10.50% year-on-year
Gelonghui, April 26 | Aotai Biotech (688606.SH) announced that in the first quarter of 2024, the company's revenue was 200 million yuan, a year-on-year decrease of 15.34%; net profit attributable to shareholders of listed companies was 44.79 million yuan, an increase of 10.50% over the previous year; and basic earnings per share were 0.56 yuan/share.
Revenues Not Telling The Story For Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606)
Aotai Biotech (688606.SH): The ban on 2.092,900 restricted shares was lifted on March 25
Gelonghui March 14 | Aotai Biotech (688606.SH) announced that the total number of shares in circulation during the current stock listing of the company is 2.092,900 shares. The stock listing and circulation date is March 25, 2024.
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?
Aotai Biotech (688606.SH) completed the repurchase and spent 595.75,500 yuan to repurchase 1.03 million shares
Aotai Biotech (688606.SH) announced that the company has completed the repurchase and has actually repurchased 1.03 million shares of the company's shares, accounting for...
Aotai Biotech (688606.SH)'s net profit for 2023 was 180 million yuan, a sharp decrease of 84.8%
Aotai Biotech (688606.SH) disclosed the 2023 annual results report, and the company achieved a total operating revenue of 7.55...
Aotai Biotech (688606.SH): It spent 53.432 million yuan to buy back a total of 1.1651% of the shares
Gelonghui, January 31, 丨 Aotai Biotech (688606.SH) announced that as of January 31, 2024, the company had repurchased a total of 923,700 shares of the company's shares through centralized bidding transactions, accounting for 1.1651% of the company's total share capital of 79,280,855 shares, an increase of 0.6606% compared with the previous disclosure. The highest price of the repurchase transaction was 60.00 yuan/share, the lowest price was 55.11 yuan/share, and the total capital paid was RMB 53.432 million (excluding stamp duty, transaction commissions, etc.) transaction fees).
Aotai Biotech (688606.SH): Net profit is expected to drop 85.23% year on year to 86.07% in 2023
Gelonghui, January 26丨Aotai Biotech (688606.SH) announced that according to preliminary estimates by the financial department, Hangzhou Aotai Biotechnology Co., Ltd. is expected to achieve operating income of 747 million yuan to 757 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease 2631.57 million yuan to 2641.57 million yuan, a year-on-year decrease of 77.66% to 77.96%. In 2023, net profit attributable to owners of the parent company is expected to reach 165 million yuan to 175 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will
Aotai Biotech (688606.SH): A total cost of 22.64 million yuan to buy back 0.5% of shares
Gelonghui, January 2, 丨 Aotai Biotech (688606.SH) announced that as of December 31, 2023, the company had repurchased 400,000 shares of the company's shares through centralized bidding transactions, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest price of the repurchase transaction was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33.
Aotai Biotech (688606.SH): Repurchased 400,000 shares at a total cost of 22.64 million yuan
Gelonghui (688606.SH) announced on November 1 | Aotai Biotech () announced that as of October 31, 2023, the company has repurchased a total of 400,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase transaction price is 58.01 yuan/share, the lowest price is 55.11 yuan/share, and the total capital paid is RMB 22,641,640.33.
Aotai Biotech (688606.SH): A total of 400,000 shares have been repurchased by the end of September
Glonghui, October 10, 丨 Aotai Biotech (688606.SH) announced that as of September 30, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): At a cost of 22.641,600 yuan, a total of 400,000 shares have been repurchased
Glonghui September 27丨Aotai Biotech (688606.SH) announced that as of the close of trading on September 27, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22.641,600 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): The company has not implemented a share repurchase
Glonghui September 4 丨 Aotai Biotech (688606.SH) announced that as of August 31, 2023, the company has not implemented a share repurchase.
Lu Weike, director of Aotai Biotech (688606.SH), has not reduced his holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that Lu Wei, the company's director, senior manager, and core technician, has reduced his holdings of the company by a total of 0 shares, accounting for 0% of the company's total share capital. As of the disclosure date of this announcement, the time period for the current holdings reduction plan has expired.
Aotai Biotech's “downhill road” in the post-pandemic era
“Investor Network” Zhang Wei In the post-pandemic era, how many companies that once relied on the COVID-19 pandemic to improve their performance still have? The answer can be seen from the newly disclosed quarterly reports. On April 29, the in vitro diagnostic reagent manufacturer Hangzhou Aotai Biotechnology Co., Ltd. (hereinafter referred to as “Aotai Biotech”, 688606.SH) released a quarterly report showing that the company's revenue for the first quarter of this year (Q1) fell 88.75% year on year, and net profit fell 96.14% year on year, in stark contrast to 2022 revenue and net profit, which increased 80.88% and 54.69% respectively. On the secondary market, on Alotai Biotech
No Data